These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 31333114)

  • 1. Comparison of the Quality of Life of Cancer Patients with Pain Treated with Oral Controlled-Release Morphine and Oxycodone and Transdermal Buprenorphine and Fentanyl.
    Leppert W; Nosek K
    Curr Pharm Des; 2019; 25(30):3216-3224. PubMed ID: 31333114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.
    Nosek K; Leppert W; Nosek H; Wordliczek J; Onichimowski D
    Drug Des Devel Ther; 2017; 11():2409-2419. PubMed ID: 28860712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioids for cancer pain - an overview of Cochrane reviews.
    Wiffen PJ; Wee B; Derry S; Bell RF; Moore RA
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012592. PubMed ID: 28683172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
    Corli O; Floriani I; Roberto A; Montanari M; Galli F; Greco MT; Caraceni A; Kaasa S; Dragani TA; Azzarello G; Luzzani M; Cavanna L; Bandieri E; Gamucci T; Lipari G; Di Gregorio R; Valenti D; Reale C; Pavesi L; Iorno V; Crispino C; Pacchioni M; Apolone G;
    Ann Oncol; 2016 Jun; 27(6):1107-1115. PubMed ID: 26940689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain.
    Ravera E; Di Santo S; Bosco R; Arboscello C; Chiarlone R
    Aging Clin Exp Res; 2011; 23(5-6):328-32. PubMed ID: 22526067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
    Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
    Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy switching in patients receiving long-acting opioids.
    Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
    Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative out-of-hospital mortality of long-acting opioids prescribed for non-cancer pain: A retrospective cohort study.
    Chung CP; Dupont WD; Murray KT; Hall K; Stein CM; Ray WA
    Pharmacoepidemiol Drug Saf; 2019 Jan; 28(1):48-53. PubMed ID: 30003613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain.
    Ackerman SJ; Mordin M; Reblando J; Xu X; Schein J; Vallow S; Brennan M
    J Manag Care Pharm; 2003; 9(3):223-31. PubMed ID: 14613465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain.
    Wiffen PJ; Derry S; Moore RA
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD011056. PubMed ID: 24874470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile.
    Kuo A; Wyse BD; Meutermans W; Smith MT
    Br J Pharmacol; 2015 Jan; 172(2):532-48. PubMed ID: 24641546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Tolerability Profile of Controlled-Release Oral Morphine and Oxycodone for Cancer Pain Treatment. An Open-Label Randomized Controlled Trial.
    Zecca E; Brunelli C; Bracchi P; Biancofiore G; De Sangro C; Bortolussi R; Montanari L; Maltoni M; Moro C; Colonna U; Finco G; Roy MT; Ferrari V; Alabiso O; Rosti G; Kaasa S; Caraceni A
    J Pain Symptom Manage; 2016 Dec; 52(6):783-794.e6. PubMed ID: 27742577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature.
    Tassinari D; Sartori S; Tamburini E; Scarpi E; Raffaeli W; Tombesi P; Maltoni M
    J Palliat Med; 2008 Apr; 11(3):492-501. PubMed ID: 18363493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study.
    Kim DY; Song HS; Ahn JS; Ryoo BY; Shin DB; Yim CY; Kim SY
    Support Care Cancer; 2010 Feb; 19(2):297-301. PubMed ID: 20213238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain.
    Wolff RF; Aune D; Truyers C; Hernandez AV; Misso K; Riemsma R; Kleijnen J
    Curr Med Res Opin; 2012 May; 28(5):833-45. PubMed ID: 22443154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.
    van Seventer R; Smit JM; Schipper RM; Wicks MA; Zuurmond WW
    Curr Med Res Opin; 2003; 19(6):457-69. PubMed ID: 14594516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in trends and pattern of strong opioid prescribing in primary care.
    Zin CS; Chen LC; Knaggs RD
    Eur J Pain; 2014 Oct; 18(9):1343-51. PubMed ID: 24756859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Opioids for Cancer Pain and its Use under Particular Conditions: A Narrative Review].
    Vieira C; Brás M; Fragoso M
    Acta Med Port; 2019 May; 32(5):388-399. PubMed ID: 31166900
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.